Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic s Q1 Revenues Fall 35 Percent as Net Losses More than Double

NEW YORK, April 21 (GenomeWeb News) - Gene Logic today reported a 35-percent drop in first-quarter revenues amid widened net losses.

 

Shares of the company plummeted in the wake of the news, falling $.99, or 24 percent, to $3.20 in mid-day trading.

 

For the quarter ended March 31, Gene Logic's total revenue fell to $12.8 million from $19.7 million in the first quarter of 2005. Revenues fell across all three of the firm's operating divisions: Genomics Division revenue declined to $8.7 million from 13.2 million in the prior-year period; Preclinical revenue fell to $4 million from $6.4 million in the prior-year period; and Drug Repositioning revenue dropped to $20,000 from $67,000 in the same period of 2005.

 

Gene Logic said in a statement that the Genomics Division has been "transitioning" over the past five quarters from a model based on database subscriptions and a few large customers to one with multiple sources of revenue --- including revenues "from perpetual licenses and microarray data generation and analysis services" --- and a broader customer base. The company added that the division's results are likely to be "variable," however, "when certain opportunities fail to materialize or are deferred."

 

The results for the Genomics Division in the first quarter reflect "lower sales due to the non-signing of a previously anticipated perpetual license and the deferral of several opportunities until later in the year," the company said.

 

Gene Logic's net losses ballooned to $11.8 million, nearly three times the company's net loss of $4.1 million in the first quarter of 2005. The company attributed the widening losses to the revenue shortfall in the Genomics Division.

 

R&D spending increased to $2.4 million from $1.5 million in the first quarter of 2005.

 

Gene Logic had $28.4 million in cash and cash equivalents as of March 31, and $63.9 million in cash, cash equivalents, and marketable securities available for sale.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.